

Financial news for GALT dated on 2020-05-11: Galectin Therapeutics Inc Files For Mixed Shelf Of Up To \$100M

Financial news for GALT dated on 2020-05-11: Galectin Therapeutics Q1 EPS \$(0.060) Up From \$(0.200) YoY

Financial news for GALT dated on 2020-05-01: 72 Biggest Movers From Yesterday

Financial news for GALT dated on 2020-04-30: 61 Stocks Moving In Thursday's Mid-Day Session

Financial news for GALT dated on 2020-04-30: Mid-Day Market Update: Crude Oil Surges 20%; Chesapeake Energy Shares Plunge

Financial news for GALT dated on 2020-04-30: Galectin Therapeutics Reports Submission Of Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol In NASH Cirrhosis

Financial news for GALT dated on 2020-04-30: 108 Biggest Movers From Yesterday

Financial news for GALT dated on 2020-04-03: B. Riley FBR Maintains Buy on Galectin Therapeutics, Lowers Price Target to \$4

Financial news for GALT dated on 2020-04-02: Galectin Therapeutics Warns Plans To Initiate NASH-RX Trial In Q2 Could Be Impacted By Coronavirus Outbreak

Financial news for GALT dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for GALT dated on 2020-03-17: HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Lowers Price Target to \$9

Financial news for GALT dated on 2020-03-16: Galectin Therapeutics Says Expects It Will Require More Cash To Fund Operations After Sept 30, 2021

Financial news for GALT dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for GALT dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for GALT dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for GALT dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for GALT dated on 2020-02-26: Stocks That Hit 52-Week Lows On Wednesday

Financial news for GALT dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for GALT dated on 2020-02-12: 94 Biggest Movers From Yesterday

Financial news for GALT dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for GALT dated on 2020-02-10: Stocks That Hit 52-Week Lows On Monday

Financial news for GALT dated on 2020-02-05: 13 Key NASH Drug Candidates To Watch For In A Potential \$30-Billion Market

Financial news for GALT dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for GALT dated on 2020-01-31: Stocks That Hit 52-Week Lows On Friday

Financial news for GALT dated on 2020-01-31: The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO

Financial news for GALT dated on 2020-01-30: Stocks That Hit 52-Week Lows On Thursday

Financial news for GALT dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for GALT dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for GALT dated on 2020-01-28: Stocks That Hit 52-Week Lows On Tuesday

Financial news for GALT dated on 2019-12-20: Stocks That Hit 52-Week Lows On Friday

Financial news for GALT dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for GALT dated on 2019-12-10: Stocks That Hit 52-Week Lows On Tuesday

Financial news for GALT dated on 2019-12-09: Galectin Therapeutics' Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin Published in Gastroenterology

Financial news for GALT dated on 2019-12-05: Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis

Financial news for GALT dated on 2019-11-13: 74 Biggest Movers From Yesterday

Financial news for GALT dated on 2019-11-12: Galectin Therapeutics Q3 EPS \$(0.05) Up From \$(0.07) YoY

Financial news for GALT dated on 2019-11-11: Galectin Therapeutics Reports Deal With Siemens Healthineers For NASH, Liver Fibrosis Collaboration

Financial news for GALT dated on 2019-09-19: 52 Biggest Movers From Yesterday

Financial news for GALT dated on 2019-09-17: Galectin Therapeutics, Providence Cancer Institute Receive Patent On Use Of Belapectin In Cancer Immunotherapy

Financial news for GALT dated on 2019-09-09: 64 Biggest Movers From Friday

Financial news for GALT dated on 2019-08-23: Stocks That Hit 52-Week Lows On Friday

Financial news for GALT dated on 2019-08-09: Galectin Therapeutics S-3 Shows Registration For ~1.7M Common Stock Offering

Financial news for GALT dated on 2019-08-09: Galectin Therapeutics Q2 EPS \$(0.06) Up From \$(0.11) YoY

Financial news for GALT dated on 2019-08-07: Stocks That Fell Through 52-Week Lows Wednesday

Financial news for GALT dated on 2019-08-05: Galectin Therapeutics Submits Phase 3 NASH-RX Protocol In Nash Cirrhosis To FDA

Financial news for GALT dated on 2019-06-18: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GALT dated on 2019-05-28: Galectin Therapeutics Raises \$44.5M In Rights Offering And \$2.5M From Warrant Exercise

Financial news for GALT dated on 2019-05-23: Galectin Therapeutics Reports Alternate Price Of Common Stock In Rights Offering

Financial news for GALT dated on 2019-05-10: Galectin Therapeutics Q1 EPS \$(0.2) Misses \$(0.14) Estimate

Financial news for GALT dated on 2019-04-30: 42 Biggest Movers From Yesterday

Financial news for GALT dated on 2019-04-24: 52 Biggest Movers From Yesterday

Financial news for GALT dated on 2019-03-22: Galectin Therapeutics Reports Co., Providence Cancer Institute Presented Highlights Showing Improved Response Of T Cells Seen In Combo Immunotherapy For Cancer Using GR-MD-02

Financial news for GALT dated on 2019-03-06: UPDATE: Galectin Chair Announces Rights Offering

Financial news for GALT dated on 2019-03-06: Galectin Therapeutics Reports Chair Richard Uihlein Sent Open Letter To Shareholders

Financial news for GALT dated on 2019-03-06: Galectin Therapeutics Files For Rights Offering

Financial news for GALT dated on 2019-02-21: 75 Biggest Movers From Yesterday

Financial news for GALT dated on 2019-02-13: Benzinga's Top Upgrades, Downgrades For February 13, 2019

Financial news for GALT dated on 2019-02-13: B. Riley FBR Initiates Coverage On Galectin Therapeutics with Buy Rating, Announces \$11 Price Target

Financial news for GALT dated on 2019-01-08: 65 Biggest Movers From Yesterday

Financial news for GALT dated on 2019-01-02: 50 Biggest Movers From Monday

Financial news for GALT dated on 2018-12-24: Galecin Therapeutics Shares Resume Trading Up 12.75%

Financial news for GALT dated on 2018-12-21: 60 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-12-20: Galectin Therapeutics Announces Extension Of \$10M Line Credit

Financial news for GALT dated on 2018-12-20: Galectin Therapeutics 8-K Shows Co. Received 1-Year Extension For Its \$10M Credit Facility

Financial news for GALT dated on 2018-11-13: Galectin Therapeutics Inc. Q3 EPS \$(0.07) Beats \$(0.09) Estimate

Financial news for GALT dated on 2018-11-07: 75 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-11-06: 52 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-11-05: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for GALT dated on 2018-09-25: Galectin Therapeutics Form 424B3 Shows Shows Registration For ~6.95M Shares Common Stock Offering By Selling Shareholders

Financial news for GALT dated on 2018-09-24: 52 Biggest Movers From Friday

Financial news for GALT dated on 2018-09-21: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for GALT dated on 2018-09-21: 56 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-09-20: 'The \$GALT stock promoters (many of the same involved with the \$AMPE pump and dump) have been salivating in anticipation of these meaningless single-arm combo data. Day traders enjoy!' -Tweet From STAT News' Adam Feuerstein

Financial news for GALT dated on 2018-09-20: Galectin Therapeutics Reports Combo Immunotherapy Of GR-MD-02 And Keytruda For All Cohorts Reported Showed An Objective Response Rate Of 50% (7/14 Patients)

Financial news for GALT dated on 2018-09-17: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for GALT dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for GALT dated on 2018-09-10: 52 Biggest Movers From Friday

Financial news for GALT dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for GALT dated on 2018-09-07: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for GALT dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for GALT dated on 2018-08-31: Galectin Therapeutics Option Alert: Sep 21 \$8 Calls Sweep (24) above Ask!: 1000 @ \$0.559 vs 1602 OI; Ref=\$6.29

Financial news for GALT dated on 2018-08-31: 62 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-08-30: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for GALT dated on 2018-08-30: 45 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-08-21: 41 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-08-16: 60 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-08-15: 55 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GALT dated on 2018-08-14: Galectin Therapeutics Q2 EPS \$(0.11) Beats \$(0.12) Estimate

Financial news for GALT dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for GALT dated on 2018-07-06: 42 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-06-28: 42 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-06-27: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GALT dated on 2018-06-27: Mid-Day Market Update: Crude Oil Up Over 3%; Aquinox Pharmaceuticals Shares Plunge

Financial news for GALT dated on 2018-06-27: Mid-Morning Market Update: Markets Open Higher; Conagra To Acquire Pinnacle Foods

Financial news for GALT dated on 2018-06-27: Galectin Therapeutics Reports Received Patent For GR-MD-02 Patent For Method, Treatment Of Pulmonary Fibrosis

Financial news for GALT dated on 2018-06-27: 54 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-06-21: 50 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-06-20: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GALT dated on 2018-06-19: Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

Financial news for GALT dated on 2018-06-15: Galectin Therapeutics Earlier 8-K Shows Pres, CEO Peter Traber Resigned; Harold Shlevin Named Replacement

Financial news for GALT dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for GALT dated on 2018-06-14: Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi

Financial news for GALT dated on 2018-06-14: 38 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-06-13: Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide

Financial news for GALT dated on 2018-06-12: Galectin Therapeutics Names COO Harold Shlevin CEO

Financial news for GALT dated on 2018-06-11: 36 Biggest Movers From Friday

Financial news for GALT dated on 2018-06-07: Galectin Therapeutics Shares Spike Higher; Traders Attributing To Article 'Galectin Therapeutics's Market Value Should Soar In The Coming Months'

Financial news for GALT dated on 2018-06-04: Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board

Financial news for GALT dated on 2018-05-15: 48 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-05-14: Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide

Financial news for GALT dated on 2018-05-14: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for GALT dated on 2018-05-14: Galectin Therapeutics Shares Up 34% After Co. Announced It Would Proceed With Phase 3 Development Of GR-MD-02 For NASH Cirrhosis Following FDA Meeting

Financial news for GALT dated on 2018-05-14: Mid-Day Market Update: Dow Rises 140 Points; Remark Holdings Shares Plunge

Financial news for GALT dated on 2018-05-14: Galectin Therapeutics Reports Will Proceed To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis

Financial news for GALT dated on 2018-05-11: Galectin Therapeutics Q1 EPS \$(0.12) Beats \$(0.13) Estimate

Financial news for GALT dated on 2018-04-24: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GALT dated on 2018-04-20: 32 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-04-13: 41 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-04-05: 8 Biotech Stocks With Clinical Trial Outcomes In April

Financial news for GALT dated on 2018-04-05: 36 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-04-02: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for GALT dated on 2018-04-02: 41 Biggest Movers From Thursday

Financial news for GALT dated on 2018-03-29: Mid-Afternoon Market Update: NASDAQ Up 2%; Movado Shares Surge On Earnings Beat

Financial news for GALT dated on 2018-03-29: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for GALT dated on 2018-03-29: Mid-Day Market Update: Dow Rises Over 1%; Zosano Pharma Shares Plummet

Financial news for GALT dated on 2018-03-29: Galectin Therapeutics Shares Up 19.3% After Co. Reported Better-Than-Expected Q4 Loss, Announces Strong Cash Position and Mentioned Ongoing Discussions With Potential Pharma Partners

Financial news for GALT dated on 2018-03-29: UPDATE: Galectin Says Believes It Has Sufficient Cash To Fund Currently-Planned Operations, R&D Activities Through At Least Mar. 31, 2019

Financial news for GALT dated on 2018-03-29: Galectin Therapeutics FY17 EPS \$(0.49) Beats \$(0.53) Est.; Says Co. Continues To Remain In Ongoing Discussions With A Number Of Pharma Cos. About Potential Partnerships

Financial news for GALT dated on 2018-03-09: 56 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-01-29: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for GALT dated on 2018-01-25: Galectin Therapeutics Shares Down 3.2%; Co. Earlier Announced It Was Granted Patents In China, Japan For Supporting NASH, Cancer Immunotherapy Clinical Development Programs

Financial news for GALT dated on 2018-01-09: 48 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-01-04: 40 Biggest Movers From Yesterday

Financial news for GALT dated on 2018-01-03: Galectin Therapeutics Shares Up 11.09%; After Dropping ~80% After Failed Phase 2b Trial Dec. 5, Stock Has Made New 52-Week High Of \$4.80 Today, Trading 78% Above Closing Price Day Before Drug Failure News, With No News To Justify

Financial news for GALT dated on 2018-01-03: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GALT dated on 2017-12-29: Galectin Therapeutics Option Alert: Apr 20 \$3 Calls Sweep (5) at the Bid: 1200 @ \$0.85 vs 1027 OI; Ref=\$3.52

Financial news for GALT dated on 2017-12-28: 30 Biggest Movers From Yesterday

Financial news for GALT dated on 2017-12-19: Galectin Therapeutics Announces \$10M Credit Line Sufficient To Cover Expenditures Into 2019

Financial news for GALT dated on 2017-12-19: 40 Biggest Movers From Yesterday

Financial news for GALT dated on 2017-12-14: UPDATE: Galectin Says 'Approximately 50% of all patients with NASH cirrhosis do not have esophageal varices which demonstrates a large potentially addressable population'

Financial news for GALT dated on 2017-12-14: Galectin Therapeutics Offers Update At Annual Meeting: CEO Reviews Results Of NASH-CX Trial Which Showed Statistically Significant, Clinically Meaningful Effects In Patients Who Had NASH Cirrhosis But Did

Not Have Esophageal Varices

Financial news for GALT dated on 2017-12-11: 36 Biggest Movers From Friday

Financial news for GALT dated on 2017-12-08: Galectin Therapeutics Director Marc Rubin Buys 7,000 @ Avg Price: \$1.85 -Form4

Financial news for GALT dated on 2017-12-08: Galectin Option Alert: Jan 19 \$2 Puts Sweep (3) at the Bid: 1009 @ \$0.401 vs 2307 OI; Ref=\$2.15 Signals

Financial news for GALT dated on 2017-12-07: Adam Feuerstein Tweets: Re: \$GALT -- H.C. Wainwright published today one of the most embarrassing research notes you'll ever read. This is what they do. And yes, a stock offering is obviously coming.

Financial news for GALT dated on 2017-12-07: Galectin Option Alert: Dec 15 \$2 Puts Sweep (6) at the Ask: 1000 @ \$0.351 vs 5195 OI; Ref=\$2.06

Financial news for GALT dated on 2017-12-07: Galectin Therapeutics Spikes to High of \$2.05 on Volume

Financial news for GALT dated on 2017-12-06: 36 Biggest Movers From Yesterday

Financial news for GALT dated on 2017-12-05: Mid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain

Financial news for GALT dated on 2017-12-05: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for GALT dated on 2017-12-05: Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide

Financial news for GALT dated on 2017-12-05: Galectin Option Alert: Dec 15 \$2 Puts at the Ask: 2000 @ \$0.75 vs 6976 OI; Ref=\$1.33

Financial news for GALT dated on 2017-12-05: Mid-Morning Market Update: Markets Mostly Higher; Toll Brothers Misses Q4 Views

Financial news for GALT dated on 2017-12-05: Galectin Shares Resume Trade, Down 43% Premarket

Financial news for GALT dated on 2017-12-05: 18 Stocks Moving In Tuesday's Pre-Market Session

Financial news for GALT dated on 2017-12-05: Adam Feuerstein Tweets: \$GALT study was total fail. Don't be fooled by the spin.

Financial news for GALT dated on 2017-12-05: Galectin Therapeutics Phase 2b NASH-CX Trial Did Not Meet its Primary Endpoint

Financial news for GALT dated on 2017-12-05: Galectin Therapeutics +40% Premarket @\$3.47; Co to Present Results from Phase 2b NASH-CX Trial on December 5, 2017 in 8:30 AM Conference Call

Financial news for GALT dated on 2017-12-04: REMINDER: Galectin Will Present Phase 2b NASH-CX Trial Results Dec. 5th On A Conf. Call 8:30am ET

Financial news for GALT dated on 2017-11-24: 40 Biggest Movers From Wednesday

Financial news for GALT dated on 2017-11-22: 35 Stocks Moving In Wednesday's Mid-Day Session

Financial news for GALT dated on 2017-11-22: 40 Biggest Movers From Yesterday

Financial news for GALT dated on 2017-11-13: Galectin Therapeutics Inc. Reports Presentation Of GR-MD-02 Data, Says Objective Response Rate In Advanced Melanoma Was 62.5% In 5 of 8 Subjects

Financial news for GALT dated on 2017-11-07: Galectin Therapeutics Reports Q3 EPS \$(0.13) vs \$(0.14) Est.

Financial news for GALT dated on 2017-10-20: Galectin Therapeutics Reports Will Present Data Showing Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis At Liver Meeting '17

Financial news for GALT dated on 2017-10-19: Roth Capital Initiates Coverage On Galectin Therapeutics with Buy Rating, Announces \$8.00 Price Target

Financial news for GALT dated on 2017-10-06: Seaport Global Initiates Coverage On Galectin Therapeutics with Buy Rating, Announces \$5.00 Price Target

Financial news for GALT dated on 2017-09-12: Galectin Therapeutics Reports Chinese Patent Office To Grant Patent For GR-MD-02

Financial news for GALT dated on 2017-08-18: Galectin Therapeutics Issues PR To Provide 'Clarification' To PR Issued Aug. 14th, See Body Text For Revision

Financial news for GALT dated on 2017-08-14: Galectin Therapeutics Q2 EPS \$(0.14) vs \$(0.15) Est., No Sales

Financial news for GALT dated on 2017-07-25: Galectin Therapeutics Reports Co. Granted Patent For Enhancing Immunotherapy In Cancer Treatment

Financial news for GALT dated on 2017-06-21: Galectin Reports Patent For Reducing Inflammatory Response Granted

Financial news for GALT dated on 2017-06-13: Galectin Therapeutics Reports 'Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial'

Financial news for GALT dated on 2017-06-06: Galectin Issued Autoimmune Disease U.S. Patent For GRM-MD-02

Financial news for GALT dated on 2017-05-19: S-3 from Galectin Therapeutics Shows Registration for \$100M in Common Shares

Financial news for GALT dated on 2017-05-15: Galectin Therapeutics Reports Q1 EPS \$(0.15) vs \$(0.16) Est.

Financial news for GALT dated on 2017-04-25: Galectin Reports Received Notice of Japanese Decision to Grant Composition of Matter Patent for GR-MD-02

Financial news for GALT dated on 2017-04-19: Watch These 5 Huge Put Purchases In Wednesday Trade

Financial news for GALT dated on 2017-04-18: Benzinga's Option Alert Recap From April 18

Financial news for GALT dated on 2017-04-18: Option Alert: Galectin Therapeutics Oct17 2.0 Puts Sweep: 550 @ ASK \$0.50: 570 traded vs 161 OI: Earnings 5/12 Before Open [est] \$3.06 Ref

Financial news for GALT dated on 2017-04-10: 14 Biggest Mid-Day Gainers For Monday

Financial news for GALT dated on 2017-04-03: H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics

Financial news for GALT dated on 2017-03-30: 15 Biggest Mid-Day Gainers For Thursday

Financial news for GALT dated on 2017-03-30: Benzinga's Top Upgrades, Downgrades For March 30, 2017

Financial news for GALT dated on 2017-03-30: Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'

Financial news for GALT dated on 2017-03-30: H.C. Wainwright Upgrades Galectin Therapeutics to Buy, Raises Price Target to \$3.50

Financial news for GALT dated on 2017-03-28: Galectin Therapeutics Reports FY16 EPS \$(0.76) vs \$(0.81) Est.

Financial news for GALT dated on 2017-03-28: Galectin Therapeutics Says Top-Line Data Readout For NASH-CX Trial Remains On Track For Early 2017

Financial news for GALT dated on 2017-03-28: Earnings Scheduled For March 28, 2017

Financial news for GALT dated on 2017-03-23: Galectin Therapeutics Issues Statement Regarding GALTW, GALTU

Financial news for GALT dated on 2017-03-16: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for GALT dated on 2017-03-14: Galectin Therapeutics Reports GR-MD-02 Showed Clinically Significant Effect in Patients with Severe, Refractory Atopic Dermatitis

Financial news for GALT dated on 2017-03-06: Galectin Therapeutics GR-MD-02 Efficacy

Shows PASI Reduction Of 50% At San Antonio Military Medical Center

Financial news for GALT dated on 2017-02-21: Galectin Therapeutics Spikes to High of \$1.73 on Volume

Financial news for GALT dated on 2017-02-15: 18 Biggest Mid-Day Losers For Wednesday

Financial news for GALT dated on 2016-12-29: Galectin Therapeutics Reports \$4 Million in New Equity Financings

Financial news for GALT dated on 2016-11-10: Galectin Reports 'Meaningful activity of GR-MD-02 in treating psoriasis and preliminary data in treating atopic dermatitis suggests promise in treatment of serious skin disease'

Financial news for GALT dated on 2016-10-05: 12 Biggest Mid-Day Losers For Wednesday

Financial news for GALT dated on 2016-10-05: Stocks Hitting 52-Week Lows

Financial news for GALT dated on 2016-10-03: Benzinga's Top Downgrades

Financial news for GALT dated on 2016-10-03: FBR Capital Downgrades Galectin Therapeutics to Market Perform

Financial news for GALT dated on 2016-09-29: 12 Biggest Mid-Day Losers For Thursday

Financial news for GALT dated on 2016-09-29: Galectin Shares Downgraded As NASH-FX Failure Likely Degrades The Prognosis For NASH-CX

Financial news for GALT dated on 2016-09-29: Benzinga's Top Downgrades

Financial news for GALT dated on 2016-09-29: H.C. Wainwright Downgrades Galectin Therapeutics to Neutral

Financial news for GALT dated on 2016-09-28: Mid-Afternoon Market Update: Dow Gains 80 Points; Crude Oil Up 5%

Financial news for GALT dated on 2016-09-28: 12 Biggest Mid-Day Losers For Wednesday

Financial news for GALT dated on 2016-09-28: Mid-Day Market Update: U.S. Stocks Turn Lower; Anavex Shares Spike Higher

Financial news for GALT dated on 2016-09-28: Why Galectin Therapeutics Just Lost Nearly Half Its Market Cap

Financial news for GALT dated on 2016-09-28: 7 Biggest Price Target Changes For Wednesday

Financial news for GALT dated on 2016-09-28: Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Estimates

Financial news for GALT dated on 2016-09-28: Benzinga's Top Downgrades

Financial news for GALT dated on 2016-09-28: Roth Capital Downgrades Galectin Therapeutics to Sell, Lowers PT to \$0.75

Financial news for GALT dated on 2016-09-28: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for GALT dated on 2016-09-27: After-Hours Decliners Sept. 27, 2016: GALT Down 46%, TPX 24%, SCSS 10.9%, SONC 6.4%, FOMX 4%, NKE, ARRY 2.6%, FRGI 2%, FL 1.9%, GXP 1.7%, GOOGL 1%

Financial news for GALT dated on 2016-09-27: Galectin Shares Resume Trade, Now Down 29%

Financial news for GALT dated on 2016-09-27: Galectin Therapeutics Shares to Resume Trade at 4:45 p.m. EDT

Financial news for GALT dated on 2016-09-27: UPDATE: Galectin Reports Trail Did Not Meet Either Primary Or Secondary Endpoints

Financial news for GALT dated on 2016-09-27: UPDATE: Galectin Says Larger Phase 2b Trial in NASH Cirrhosis Now Completely Enrolled

Financial news for GALT dated on 2016-09-27: Galectin Therapeutics Reports No Apparent Improvement In 3 Non-Invasive Tests for Assessment Of Liver Fibrosis

Financial news for GALT dated on 2016-09-27: 8-K from Galectin Therapeutics Shows Securities Purchase Deal with 10X Fund for Aggregate of 1.5M Shares of Series B-3

Convertible Preferred Shares

Financial news for GALT dated on 2016-09-27: Galectin Therapeutics Shares Halted News Pending

Financial news for GALT dated on 2016-09-26: Galectin Therapeutics Sells off to Low of \$2.33 on Volume

Financial news for GALT dated on 2016-09-22: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for GALT dated on 2016-09-21: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for GALT dated on 2016-09-20: NASH Sympathy Plays On Tobira Therapeutics Deal

Financial news for GALT dated on 2016-09-20: Conatus Pharma Shares Trading Up 27% on the Heels of Deal for Tobira Therapeutics; Also Watching Galmed Pharma, Galectin Therapeutics, Enanta Pharma, Intercept

Financial news for GALT dated on 2016-08-25: 18 Biggest Mid-Day Losers For Thursday

Financial news for GALT dated on 2016-08-25: Galectin Therapeutics Reports Disappointing Results From 12-Week Extension Of Phase 2A Psoriasis Clinical Trial

Financial news for GALT dated on 2016-08-25: 8-K from Galectin Therapeutics Shows 'Meaningful activity of GR-MD-02 in treating psoriasis...' Demonstrated from 12-Week Extension of Phase 2a Trial

Financial news for GALT dated on 2016-08-09: Galectin Therapeutics Reports Q2 EPS \$(0.20) vs. Est. \$(0.24)

Financial news for GALT dated on 2016-08-02: Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02

Financial news for GALT dated on 2016-07-12: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis

Financial news for GALT dated on 2016-07-01: 12 Biggest Mid-Day Gainers For Friday

Financial news for GALT dated on 2016-07-01: Mid-Morning Market Update: Markets Open Higher; Micron To Lower Jobs

Financial news for GALT dated on 2016-07-01: Roth Capital Assumes Galectin Therapeutics at Buy

Financial news for GALT dated on 2016-06-02: Galectin Therapeutics Reports Positive Preclinical Results On Role Of Galectin-3 In Pulmonary Arterial Hypertension

Financial news for GALT dated on 2016-05-16: UPDATE: Galectin Therapeutics Says 'Each of the four patients who received six doses of GR-MD-02 over 12 weeks of therapy reported improvement in their symptoms related to psoriasis'

Financial news for GALT dated on 2016-05-16: Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis

Financial news for GALT dated on 2016-05-11: Galectin Therapeutics Reports Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis

Financial news for GALT dated on 2016-05-10: Galectin Therapeutics Reports Q1 EPS \$(0.24) vs \$(0.17) Est.

Financial news for GALT dated on 2016-03-28: H.C. Wainwright Assumes Galectin Therapeutics at Buy, Announces \$8.00 PT

Financial news for GALT dated on 2016-03-15: Galectin Therapeutics Reports FY15 EPS \$(0.88) vs. Prior Year Quarter \$(0.78)

Financial news for GALT dated on 2016-03-15: Galectin Therapeutics Reports FY15 EPS \$(0.88) vs \$(0.78) in Same Qtr. Last Year

Financial news for GALT dated on 2016-03-09: Roth's Piros: Galectin Therapeutics Shares Can Quadruple In Next 12 Months

Financial news for GALT dated on 2016-02-24: Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis

Financial news for GALT dated on 2016-01-05: 8-K from Galectin Therapeutics Shows Co. Received Dismissals of Federal Securities Class Action, Holder Derivative Actions

Financial news for GALT dated on 2015-11-27: CVI Investments Reports 5.5% Passive Stake In Galectin Therapeutics as of November 20, 2015

Financial news for GALT dated on 2015-11-20: Morning Market Losers

Financial news for GALT dated on 2015-11-20: Galectin Therapeutics Prices \$9.8M Registered Direct Offering: to Purchase ~3.57M Shares of Common at Exercise Price \$2.50/Share, ~4.762M Shares at \$2.06/Share

Financial news for GALT dated on 2015-11-09: Galectin Reports Q3 EPS \$(0.26) vs \$(0.20) Est.

Financial news for GALT dated on 2015-10-19: UPDATE: Galectin Says Co. Filed NDA Application for GR-MD-02 In Combo with Keytruda with FDA

Financial news for GALT dated on 2015-10-19: 8-K from Galectin Therapeutics Shows GR-MD-02 Will Be Studied in Combo with Keytruda in Patients with Metastatic Melanoma

Financial news for GALT dated on 2015-10-07: Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

Financial news for GALT dated on 2015-09-28: Galectin Therapeutics Still A Favorite Pick Of H.C. Wainwright Analysts

Financial news for GALT dated on 2015-09-24: Galectin Therapeutics Reports Commencement of Phase 2a Psoriasis Study with GR-MD-02

Financial news for GALT dated on 2015-09-21: Galectin Therapeutics Could Triple On Fibrosis And Cirrhosis Treatment

Financial news for GALT dated on 2015-09-21: Benzinga's Top Initiations

Financial news for GALT dated on 2015-09-21: Morning Market Gainers

Financial news for GALT dated on 2015-09-21: H.C. Wainwright Initiates Coverage on Galectin Therapeutics at Buy, Announces \$7.00 PT

Financial news for GALT dated on 2015-09-16: Galectin Therapeutics Announces Start of Phase 2 Clinical Trial with GR-MD-02 in NASH with Advanced Fibrosis

Financial news for GALT dated on 2015-08-13: Mid-Day Market Update: Thursday's Movers, China, Tesla And More

Financial news for GALT dated on 2015-08-13: Morning Market Gainers

Financial news for GALT dated on 2015-08-13: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

Financial news for GALT dated on 2015-08-10: Galectin Therapeutics Reports Q2 :pss \$0.21 Vs est Loss \$0.23

Financial news for GALT dated on 2015-07-15: Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development

Financial news for GALT dated on 2015-06-29: Galectin Therapeutics Begins Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis

Financial news for GALT dated on 2015-05-14: Galectin Therapeutics Announces no Drug-Drug Interaction Between GR-MD-02 and Midazolam

Financial news for GALT dated on 2015-05-11: Filing from Galectin Therapeutics Shows Q1 Loss of \$0.22/Share vs Loss of \$0.20/Share Est.

Financial news for GALT dated on 2015-03-24: Galectin Therapeutics Presents Research With GR-MD-02 in NASH at AASLD

Financial news for GALT dated on 2015-03-18: Galectin Therapeutics Reports FY14 GAAP EPS \$(0.78) vs. Est. \$(0.77)

Financial news for GALT dated on 2015-03-12: Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH

Financial news for GALT dated on 2015-02-24: 8-K from Galectin Therapeutics Offers Details from Design of Phase 2 Trial with GR-MD-02, Says Will Submit an SPA by Month

End

Financial news for GALT dated on 2015-01-08: Galectin Therapeutics Halted on Up Down Limit

Financial news for GALT dated on 2015-01-07: Morning Market Gainers

Financial news for GALT dated on 2015-01-07: Wednesday Morning Movers

Financial news for GALT dated on 2015-01-07: Galectin Therapeutics Shares Rise 46% Premarket on Positive Phase 1 for GR-MD-02

Financial news for GALT dated on 2015-01-07: Galectin Therapeutics Announces Phase 1 Trial Shows Drug Safe For Fibrosis and May Have Therapeutic Effects

Financial news for GALT dated on 2014-12-24: Stocks Hitting 52-Week Lows

Financial news for GALT dated on 2014-11-10: Galectin Therapeutics Inc. Reports Q3 EPS of \$(0.17) vs \$(0.27) Est

Financial news for GALT dated on 2014-11-09: Galectin Therapeutics' Phase 1 Data Advances GR-MD-02 Into Phase 2 Clinical Development

Financial news for GALT dated on 2014-09-16: MLV & Co Has Positive Outlook On Galectin Therapeutics Inc

Financial news for GALT dated on 2014-09-15: Galectin Confirms Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy

Financial news for GALT dated on 2014-09-15: Galectin Issued Patent for GR-MD-02

Financial news for GALT dated on 2014-09-12: 8-K from Galectin Therapeutics Shows Slideshow Presentation: Shows 'Ongoing Discussions with Large Pharma Cos.'

Financial news for GALT dated on 2014-08-20: Galectin Shares Move to High on Volume

Financial news for GALT dated on 2014-08-15: Galectin Therapeutics CEO Traber Buys 4,000 Shares @\$4.46/Share

Financial news for GALT dated on 2014-08-07: Galectin Therapeutics Inc. Reports Q2 EPS of \$(0.17) vs \$(0.21) Est

Financial news for GALT dated on 2014-08-05: UPDATE: Galectin Awarded U.S. Patent for GR-MD-02 Composition of Matter

Financial news for GALT dated on 2014-08-05: Galectin Announces Patent For GR-MD-02

Financial news for GALT dated on 2014-08-04: Galectin Statement About Class Action Lawsuit

Financial news for GALT dated on 2014-08-01: UPDATE: Aegis Capital Downgrades Galectin Therapeutics

Financial news for GALT dated on 2014-07-30: Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation

Financial news for GALT dated on 2014-07-30: UPDATE: Galectin Says Market Reacted Negatively to Positive Results of Clinical Trial

Financial news for GALT dated on 2014-07-30: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program

Financial news for GALT dated on 2014-07-30: UPDATE: MLV & Co Reiterates On Galectin Therapeutics Following Cohort 2 Results

Financial news for GALT dated on 2014-07-29: Morning Market Losers

Financial news for GALT dated on 2014-07-29: UPDATE: Galectin Slideshow Reveals Several Concerning Points

Financial news for GALT dated on 2014-07-29: UPDATE: Galectin Shares Fall 32% Premarket Following Release of 8-K

Financial news for GALT dated on 2014-07-29: 8-K from Galectin Shows GR-MD-02 Was Safe, Well Tolerated in Recent Trial, Primary Endpoints in Cohort 2 Were Met

Financial news for GALT dated on 2014-07-28: Galectin Shares Move Lower; May be Attributed to Seeking Alpha Post

Financial news for GALT dated on 2014-07-25: Adam Feuerstein Tweet: After spending time with \$ICPT NASH study this week for Mailbag, \$GALT NASH trial is farce by comparison.

Financial news for GALT dated on 2014-07-25: Galectin Will Host Webcase to Discuss Phase 1 GR-MD-02 Findings

Financial news for GALT dated on 2014-07-22: Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combo with Ipilimumab in Metastatic Melanoma

Financial news for GALT dated on 2014-06-23: Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement

Financial news for GALT dated on 2014-05-28: Galectin Announces Receiving of US Patent for GR-MD-02

Financial news for GALT dated on 2014-05-28: Galectin Revives Patent For GR-MD-02

Financial news for GALT dated on 2014-05-13: Galectin Therapeutics Inc. Reports Q1 EPS of \$(0.27) vs \$(0.20) Est

Financial news for GALT dated on 2014-04-23: Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02

Financial news for GALT dated on 2014-04-17: Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis; Expects GR-MD-02 Phase 1 Cohort 2 Result at End of July

Financial news for GALT dated on 2014-04-02: McNicoll Lewis Vlak Maintains Buy on Galectin Therapeutics Inc., Raises PT to \$27.00

Financial news for GALT dated on 2014-04-01: MLV & Co Expects Positive News from Galectin Therapeutics

Financial news for GALT dated on 2014-03-31: Galectin Announces First Cohort Results in Phase 1 Trial Shows GR-MD-02 Safe and Well Tolerated in Patients

Financial news for GALT dated on 2014-03-25: Adam Feuerstein Tweet: '\$GALT: Mark The Date. Drug Data Are Coming and We're Selling Stock'

Financial news for GALT dated on 2014-03-25: Benzinga's Volume Movers

Financial news for GALT dated on 2014-03-25: Galectin Therapeutics to Announce Results from First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease

Financial news for GALT dated on 2014-03-25: Form 8-K from Galectin Shows Will Report Data on First Cohort in Fatty Liver Disease in Conf. Call on Apr. 1st

Financial news for GALT dated on 2014-03-21: Galectin Therapeutics Inc. Reports FY EPS of \$(1.30) vs \$(1.29) Est

Financial news for GALT dated on 2014-02-26: Form 8-K from Galectin Therapeutics Shows Received Patent for GR-MD-02 in Fatty Liver Disease

Financial news for GALT dated on 2014-02-25: Galectin Therapeutics Awarded NASH-Related Patent

Financial news for GALT dated on 2014-02-12: Aegis Capital Maintains Buy on Galectin Therapeutics Inc., Raises PT to \$32.00

Financial news for GALT dated on 2014-02-03: UPDATE: Galectin Expects Trial to Begin Enrollment In March

Financial news for GALT dated on 2014-02-03: Galectin Therapeutics, Providence Portland Medical Center Receive OK from FDA to Proceed with Phase 1B Clinical Trial in Metastatic Melanoma

Financial news for GALT dated on 2014-01-27: UPDATE: Galectin Therapeutics, SBH Sciences from Galectin Sciences

Financial news for GALT dated on 2014-01-27: Galectin, SBH Sciences in Venture

Financial news for GALT dated on 2014-01-21: Galectin Therapeutics Spikes Higher

Financial news for GALT dated on 2014-01-15: Galectin Therapeutics Supports IND for GR-MD-02 in Metastatic Melanoma

Financial news for GALT dated on 2014-01-15: UPDATE: Galectin Therapeutics Supports

Investigational New Drug Application for its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma

Financial news for GALT dated on 2014-01-15: Galectin Therapeutics: IND Submitted by Providence Portland Medical Center

Financial news for GALT dated on 2014-01-13: Galectin Therapeutics Complet Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Patients with NASH

Financial news for GALT dated on 2014-01-10: Market Wrap For January 10: Job Growth Weak, But Unemployment Falls

Financial news for GALT dated on 2014-01-10: Benzinga's Volume Movers

Financial news for GALT dated on 2014-01-10: Galectin Sold 2.39M Shares at \$9.99/Share

Financial news for GALT dated on 2013-11-26: Adam Feuerstein Tweet: 'I've never heard of Stonegate Securities but disclosures B & C on this \$GALT report are refreshingly honest --> pic.twitter.com/w8Zkl9KJYE'

Financial news for GALT dated on 2013-11-12: Galectin Therapeutics Inc. Reports Q3 EPS of \$(0.22) vs \$(0.20) Est

Financial news for GALT dated on 2013-11-12: Galectin Therapeutics Inc. Reports Q3 EPS of \$(0.22) vs \$(0.20) Est

Financial news for GALT dated on 2013-10-25: Galectin Therapeutics Could Sell Up to \$30M in Shares

Financial news for GALT dated on 2013-10-17: Galectin Announces Early Warrant Exercise by 10X Fund, Issues Update on Cash Position

Financial news for GALT dated on 2013-10-07: UPDATE: Ascendant Capital Initiates Coverage on Galectin Therapeutics on Intriguing Speculative Short-Cap Investment Story

Financial news for GALT dated on 2013-10-07: Benzinga's Top Initiations

Financial news for GALT dated on 2013-10-07: Ascendant Capital Initiates Coverage on Galectin Therapeutics Inc. at Buy, Announces \$13.00 PT

Financial news for GALT dated on 2013-09-26: Trading Halts on GALT, BOTJ, AMU, LIQD, and WINA

Financial news for GALT dated on 2013-09-12: Benzinga's Volume Movers

Financial news for GALT dated on 2013-09-12: Morning Market Movers

Financial news for GALT dated on 2013-09-11: Benzinga's Volume Movers

Financial news for GALT dated on 2013-08-21: Galectin Therapeutics Reports \$3M Placement of Restricted Stock, Priced 500K Shares at \$6/Share

Financial news for GALT dated on 2013-08-19: UPDATE: Aegis Capital Raises PT on Galectin Therapeutics Following Valuation Update

Financial news for GALT dated on 2013-08-12: Morning Market Movers

Financial news for GALT dated on 2013-08-12: Galectin Therapeutics Reports FDA Fast Track Designation for GR-MD-02

Financial news for GALT dated on 2013-07-24: Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis

Financial news for GALT dated on 2013-07-01: Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis

Financial news for GALT dated on 2013-06-21: Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial Officer

Financial news for GALT dated on 2013-03-05: Benzinga's Small Cap Movers for Tuesday March 5, 2013

Financial news for GALT dated on 2013-03-05: Aegis Capital Reiterates Buy Rating on Galectin Therapeutics After FDA Approval

Financial news for GALT dated on 2013-02-19: Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with University of Georgia

Financial news for GALT dated on 2013-01-31: Galectin Therapeutics Submits IND Application for Treatment of Fatty Liver Disease

Financial news for GALT dated on 2013-01-28: Galectin Therapeutics Publishes Proceeds by ACS on Symposium

Financial news for GALT dated on 2013-01-22: Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies

Financial news for GALT dated on 2012-11-09: Galectin Therapeutics Reports Q3 EPS \$-0.19 vs \$-0.18 Est

Financial news for GALT dated on 2012-08-29: Galectin Therapeutics Names Shlevin COO

Financial news for GALT dated on 2012-07-25: Aegis Capital Initiates Coverage on Galectin Therapeutics at Buy

Financial news for GALT dated on 2012-07-23: Galectin Therapeutics Pops 50% on U.S. Patent

Financial news for GALT dated on 2012-07-23: Galectin Therapeutics Halted on Circuit Breaker

Financial news for GALT dated on 2012-07-23: Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease with Fibrosis and Cirrhosis

Financial news for GALT dated on 2012-07-06: UPDATE: Dawson James Reiterates Buy Rating, Lowers PT on Galectin Therapeutics

Financial news for GALT dated on 2012-07-06: Dawson James Maintains Galectin Therapeutics at Buy, Lowers PT to \$3

Financial news for GALT dated on 2012-05-22: Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders

Financial news for GALT dated on 2012-03-23: From Earlier: Galectin Therapeutics Announces Pricing of Public Offering of 1.16M Units, Listing on Nasdaq and Effectiveness of Reverse Stock Split